Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial - The Lancet

Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: A retrospective cohort study

Table 4 from Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open- label, randomised controlled trial

Prevention Starts in the Womb: Opportunities for Addressing Cardiovascular Risk Factors During Pregnancy and Beyond - Methodist DeBakey Cardiovascular J

PDF) Comparison of effect of nifedipine, labetalol and methyldopa in treatment of hypertension in pregnancy in a tertiary care government hospital

A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre‐eclampsia - Poon - 2021 - International Journal of Gynecology & Obstetrics - Wiley Online Library

The Lancet, 21 September 2019, Volume 394, Issue 10203, Pages 979-1112

Comparative maternal outcomes of oral nifedipine and intravenous labetalol for severe hypertension during pregnancy: an open label randomized controlled trial. - Document - Gale Academic OneFile

Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial - The Lancet

Sympatholytics: Alpha-2 agonists: Video & Anatomy

PDF) Comparative maternal outcomes of oral nifedipine and intravenous labetalol for severe hypertension during pregnancy: an open label randomized controlled trial

Last Month in Nephrology – Page 2

Pre-eclampsia Nature Reviews Disease Primers

Impact of Chronic Hypertension and Antihypertensive Treatment on Adverse Perinatal Outcomes: Systematic Review and Meta‐Analysis

Effectiveness of nifedipine, labetalol, and